FDA’s ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindo

FDA’s ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindo
aliu
Fri, 09/24/2021 – 11:24